Journal of the Korean Society of Radiology (한국방사선학회논문지)

The Korean Society of Radiology (한국방사선학회)
권호 표지
DOI QR코드

DOI QR Code

Availability and Reproducibility Evaluation of High-dose-rate Intraluminal Brachytherapy for Unresectable Recurrent Cholangiocarcinoma

재발한 간담도암 환자에서 시행 한 high-dose-rate intraluminal brachytherapy의 유용성 및 재현성 평가

  • Park, Ju-Kyeong (Department of Radiation Oncology, Chonbuk National University Medical School) ;
  • Lee, Seung-Hun (Department of Radiation Oncology, Chonbuk National University Medical School) ;
  • Cha, Seok-Yong (Department of Radiation Oncology, Chonbuk National University Medical School) ;
  • Kim, Yang-Su (Department of Radiation Oncology, Chonbuk National University Medical School) ;
  • Lee, Sun-Young (Department of Radiation Oncology, Chonbuk National University Medical School)
  • 박주경 (전북대학교병원 방사선종양학과) ;
  • 이승훈 (전북대학교병원 방사선종양학과) ;
  • 차석용 (전북대학교병원 방사선종양학과) ;
  • 김양수 (전북대학교병원 방사선종양학과) ;
  • 이선영 (전북대학교병원 방사선종양학과)
  • Received : 2012.03.12
  • Accepted : 2012.04.24
  • Published : 2012.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

General treatment for cholangiocarcinoma is complete surgical resection. However recurrence is common in those patients. In most of cases the purpose of the treatment for patients with recurrent is palliative. Therefore we adopt intraluminal catheter to treat a recurrent patient with high-dose-rate intraluminal brachytherapy. This study aims to evaluate the treatment procedure and set-up reproducibility of intraluminal brachytherapy in the recurrent patient. Study patient was diagnosed at rcT1N0M0 and undergone intraluminal brachytherapy after Arrow Sheath insertion. 3 Gy was delivered in every fraction with a total dose of 30 Gy. We planned dose normalization at distal, proximal and central axis point of narrowed bile duct far from 1 cm. To evaluate set-up reproducibility, we measured distance between distal, proximal treatment target volume point and anterior surface of the thoracic vertebral body respectively for five times before every treatment with dummy seed insertion. Mean distance between distal, proximal treatment target volume point and anterior surface of 10th and 11th thoracic vertebral bodies is 0.5 cm, 6.1 cm and standard deviation is 0.06, 0.08 respectively. In addition, set-up reproducibility was maintained significantly. The patient has been alive with no evidence of disease recurrence for more than a year and has not yet reported severe complications. In conclusion, high-dose-rate intraluminal brachytherapy for unresectable recurrence of cholangiocarcinoma maintains high set-up reproducibility without severe side effects.

간담도암의 일차적 치료법은 수술적 제거이나, 초기 병기로 수술을 하여도 재발이 흔하며, 재발 후에는 근치적 목적이 아닌 주로 증상 완화 목적의 치료를 하고 있다. 이에 본 연구에서는 재발한 환자에서 자체 도입한 특수 관을 이용한 근치적 목적의 high-dose-rate intraluminal brachytherapy의 치료법과 치료 set-up 재현성 유지에 대하여 고찰하고 자 한다. 본 연구는 간담도암으로 수술 후, 6개월 간격으로 복부 자기 공명 영상을 이용한 추적 검사를 시행하여, 수술문합 부위의 재발이 확인된 임상 병기 rcT1N0M0인 환자를 대상으로 하였다. 근접 치료를 위하여 경피적 담도 배액관을 치료 전용관인 Arrow Sheath로 교체 후, intraluminal catheter를 삽입하여, 일회 치료당 3 Gy 씩 총 30 Gy 근접치료를 시행하였다. 협착 된 담도의 distal and proximal 그리고 central axis point로부터 1 cm 떨어진 지점을 선량표준화였으며, 5회에 걸쳐 치료 전 dummy seed 삽입 후, 치료 표적 용적 근위부와 말단부의 기준점에서 흉추 사이의 거리를 측정하여 set-up 재현성을 평가하였다. 매주 치료 전 근위부와 말단부위 치료 표적 용적 기준점에서 흉추 사이의 거리를 5회 측정한 값과 simulation image에서 측정된 거리를 비교한 결과 평균값과 표준편차가 오차율 5% 이내로 유의한 수준으로 측정되어 매회 치료시 재현성이 유지 되었다, 본 연구 환자의 추적 검사 상 1년 이상 무병 생존하고 있으며, 심각한 부작용 또한 관찰되지 않았다. 따라서, 수술이 불가능한 재발한 간담도암 환자에서 본원에서 자체 도입한 관으로 시행한 근접치료는 주변 인접 장기의 심각한 부작용 발생 없이, 매 회 치료 시 재현성이 유의한 수준으로 유지 되는 것으로 평가되었다.

Keywords

References

  1. Takada T, Miyazaki M, Miyakawa S, Tsukada K, Nagino M, Kondo S, Furuse J, Saito H, Tsuyuguchi T, Kimura F, Yoshitomi H, Nozawa S, Yoshida M, Wada K, Amano H, Miura F. Purpose, use, and preparation of clinical practice guidelines for the management of biliary tract and ampullary carcinomas.J Hepatobiliary Pancreat Surg. Vol. 15, no. 1, pp.2-6, 2008. https://doi.org/10.1007/s00534-007-1274-x
  2. Klempnauer J, Ridder GJ, Werner M, Weimann A, Pichlmayr R. What constitutes long term survival after surgery for hilar cholangiocarcinoma? Cancer. Vol. 79, pp.26-34, 1997. https://doi.org/10.1002/(SICI)1097-0142(19970101)79:1<26::AID-CNCR5>3.0.CO;2-K
  3. Lee SG, Lee YJ, Pa가 KM, Hwang S, Min PC. One houndred and eleven liver resections for hilar bile duct cancer. J Hepatobiliary Pancreat Surg. Vol. 7, pp.135-141, 2000. https://doi.org/10.1007/s005340050167
  4. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberge WMC, Taylor-Robinson SD, Thillaianayagam AV, Thomas HC, Thursz MR, Wasan H. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut. Vol. 51(Suppl. 6), VI1-9, 2002. https://doi.org/10.1136/gut.51.suppl_6.vi1
  5. Shirabe K, Shimada M, Harimoto N, Sugimachi K, Yamashita Y, Tsujita E, Aishima S. Intrahepatic cholangiocarcinoma: its mode of spreading and therapeutic modalities. Surgery. Vol. 131(Suppl 1), S159-164, 2002. https://doi.org/10.1067/msy.2002.119498
  6. Sagawa N, Kondo S, Morikawa T, Okushiba S, Katoh H. Effectiveness of radiation therapy after surgery for hilar cholangiocarcinoma. Surg Today. Vol. 35, pp.548-552, 2005. https://doi.org/10.1007/s00595-005-2989-4
  7. Ove R, Kennedy A, Darwin P, Haluszka O. Postoperative endoscopic retrograde high dose rate brachytherapy for cholangiocarcinoma. Am J Clin Oncol. Vol 23, pp.559-561, 2000. https://doi.org/10.1097/00000421-200012000-00004
  8. Lu JJ, Bains YS, Abdel-Wahab M, Brandon AH, Wolfson AH, Raub WA, Wilkinson CM, Markoe AM. High dose rate remote afterloading intracavitary brachytherapy for the treatment of extrahepatic biliary duct carcinoma. Cancer J. Vol. 8, pp.74-48, 2002. https://doi.org/10.1097/00130404-200201000-00013
  9. Sauz-Altamira PM, Ferante K, Jenkins RL, Lewis WD, Huberman MS, Stuart KE. A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma. Cancer. Vol. 82, pp.2321-2325, 1998. https://doi.org/10.1002/(SICI)1097-0142(19980615)82:12<2321::AID-CNCR4>3.0.CO;2-V
  10. Todoroki T. Chemotherapy for bile duct carcinoma in the light of adjuvant chemotherapy to surgery. Hepatogastroenterology. Vol. 47, pp.644-649, 2000.
  11. Bruha R, Petrtyl J, Kubecova M, Marecek Z, Dufek V, Urganek P, Kodadova J, Chodounsky Z. Intraluminal brachytherapy and selfexpendable stents in nonresectable biliary malignancies - The question of long term palliation. Hepatogastroenterology. Vol. 48, pp.631-637, 2001.
  12. Yoon WS, Kim TH, Yang DS, Choi MS, Kim CY. High-dose-rate intraluminal brachytherapy for biliary obstruction by secondary malignant biliary tumors. J The Korean Soc Ther Radiol Oncol, Vol. 21, No. 1, pp.35-43, 2003.

Cited by

  1. Dose Evaluation of the Man Adjacent to an Implanted Patient During the Prostate Cancer Brachytherapy vol.10, pp.1, 2016, https://doi.org/10.7742/jksr.2016.10.1.39